17.1 pembrolizumab

Survival status and ctDNA levels for patients receiving pembrolizumab

A data frame with 94 rows and 15 variables:

• id Patient ID
• age Age at study entry
• sex Patient Sex
• cohort Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor
• l_size Target lesion size at baseline
• pdl1 PD L1 percent
• tmb log of TMB
• baseline_ctdna Baseline ctDNA
• change_ctdna_group Did ctDNA increase or decrease from baseline to cycle 3
• orr Objective Response
• cbr Clinical Beneficial Response
• os_status Overall survival status, 0 = alive, 1 = deceased
• os_time Overall survival time in months
• pfs_status Progression free survival status, 0 = progression free, 1 = progressed
• pfs_time Progression free survival time in months